Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer R Ribeiro

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|September 22, 2022
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathwaysNicole E James, Morgan Woodman, Payton De La Cruz, et al.
Breast Cancer Research : BCR|December 2, 2024
NF-κB associated markers of prognosis in early and metastatic triple negative breast cancerPayton De La Cruz, Julia McAdams, Melanie Morales Aquino, et al.
Frontiers in Oncology|February 7, 2018
Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer <i>via</i> Regulation of the Extracelluar MatrixJennifer R Ribeiro, Hilary M Gaudet, Mehreen Khan, et al.
Oncotarget|June 6, 2019
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genesNicole E James, Lindsey Beffa, Matthew T Oliver, et al.
Gynecologic Oncology|April 1, 2023
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosisShaina F Bruce, Sharon Wu, Jennifer R Ribeiro, et al.
Gynecologic Oncology|September 8, 2023
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutationMichael D Toboni, Sharon Wu, Alex Farrell, et al.
Oncotarget|May 21, 2019
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteinsNicole E James, Evelyn Cantillo, Naohiro Yano, et al.
Nature Communications|March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvalsGeorge W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Communications Medicine|August 1, 2025
Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancerYating Cheng, Norsang Lama, Ming Chen, et al.
The Oncologist|October 7, 2025
Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancerRana R McKay, Shayan S Nazari, Andrew Elliott, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|September 22, 2022
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathwaysNicole E James, Morgan Woodman, Payton De La Cruz, et al.
Breast Cancer Research : BCR|December 2, 2024
NF-κB associated markers of prognosis in early and metastatic triple negative breast cancerPayton De La Cruz, Julia McAdams, Melanie Morales Aquino, et al.
Frontiers in Oncology|February 7, 2018
Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer <i>via</i> Regulation of the Extracelluar MatrixJennifer R Ribeiro, Hilary M Gaudet, Mehreen Khan, et al.
Oncotarget|June 6, 2019
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genesNicole E James, Lindsey Beffa, Matthew T Oliver, et al.
Gynecologic Oncology|April 1, 2023
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosisShaina F Bruce, Sharon Wu, Jennifer R Ribeiro, et al.
Gynecologic Oncology|September 8, 2023
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutationMichael D Toboni, Sharon Wu, Alex Farrell, et al.
Oncotarget|May 21, 2019
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteinsNicole E James, Evelyn Cantillo, Naohiro Yano, et al.
Nature Communications|March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvalsGeorge W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Communications Medicine|August 1, 2025
Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancerYating Cheng, Norsang Lama, Ming Chen, et al.
The Oncologist|October 7, 2025
Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancerRana R McKay, Shayan S Nazari, Andrew Elliott, et al.
Pageof 4